



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**21.02.2018 Bulletin 2018/08**

(45) Date of publication and mention  
of the grant of the patent:  
**20.12.2017 Bulletin 2017/51**

(21) Application number: **10784166.0**

(22) Date of filing: **04.06.2010**

(51) Int Cl.:  
**A61K 31/70** <sup>(2006.01)</sup> **A61K 48/00** <sup>(2006.01)</sup>  
**A61K 38/16** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2010/037437**

(87) International publication number:  
**WO 2010/141842 (09.12.2010 Gazette 2010/49)**

(54) **INTERLACED METHOD FOR TREATING CANCER OR A PRECANCEROUS CONDITION**

VERSCHACHTELTES VERFAHREN ZUR BEHANDLUNG VON KREBS ODER EINEM  
PRÄKANZERÖSEN LEIDEN

PROCÉDÉ COMBINÉ DE TRAITEMENT D'UN CANCER OU D'UN ÉTAT PRÉCANCÉREUX

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO SE SI SK SM TR**

(30) Priority: **05.06.2009 US 184658 P**

(43) Date of publication of application:  
**11.04.2012 Bulletin 2012/15**

(73) Proprietor: **Cavion, Inc.**  
**Charlottesville, VA 22902 (US)**

(72) Inventors:  
• **KROUSE, Andrew J.**  
**Charlottesville,**  
**Virginia 22911 (US)**  
• **GRAY, Lloyd S.**  
**Louisa,**  
**Virginia 23093 (US)**  
• **MACDONALD, Timothy**  
**Charlottesville,**  
**Virginia 22902 (US)**  
• **LINDEN, Joel**  
**Charlottesville,**  
**Virginia 22901 (US)**

(74) Representative: **Hoffmann Eitle**  
**Patent- und Rechtsanwälte PartmbB**  
**Arabellastraße 30**  
**81925 München (DE)**

(56) References cited:  
**WO-A2-2006/023883 US-A1- 2006 003 020**  
**US-A1- 2008 194 669**

- **MCCALMONT W F; HEADY T N; PATTERSON J R; LINDENMUTH M A; HAVERSTICK D M; GRAY L S; MACDONALD T L: "Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 14, 16 July 2004 (2004-07-16) , pages 3691-3695, XP002692339, DOI: 10.1016/j.bmcl.2004.05.011**
- **HAVERSTICK D M; HEADY T N; MACDONALD T L; GRAY L S: "Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca<sup>2+</sup> entry<1>", CANCER RESEARCH, vol. 60, 15 February 2000 (2000-02-15), pages 1002-1008, XP002692338,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- |   |  |
|---|--|
| <ul style="list-style-type: none"> <li>• YOSHIDA, J. ET AL.: 'G1 cell cycle arrest by amlodipine, a dihydropyridine Ca<sup>2+</sup> channel blocker, in human epidermoid carcinoma A431 cells.' <i>BIOCHEM. PHARMACOL.</i> vol. 73, no. 7, 14 December 2006, pages 943 - 953, XP005905171</li> <li>• KANDA, H. ET AL.: 'Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest.' <i>INT. J. CANCER.</i> vol. 122, no. 2, 15 January 2008, pages 444 - 451, XP055074821</li> <li>• ZHANPING, W. ET AL.: 'Voltage-gated K<sup>+</sup> channels are associated with cell proliferation and cell cycle of ovarian cancer cell.' <i>GYNECOL. ONCOL.</i> vol. 104, no. 2, 02 October 2006, pages 455 - 460, XP005853890</li> </ul> | <ul style="list-style-type: none"> <li>• KLIMATCHEVA, E. ET AL.: 'Wonderlin, W. F., An ATP-sensitive K(+) current that regulates progression through early G1 phase of the cell cycle in MCF-7 human breast cancer cells.' <i>J. MEMBR. BIOL.</i> vol. 171, no. 1, 01 September 1999, pages 35 - 46, XP055074824</li> <li>• WANG, Z. ET AL.: 'Ca<sup>2+</sup> influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts.' <i>AM. J. PHYSIOL.</i> vol. 265, November 1993, pages C1239 - C1246, XP008164012</li> </ul> |
|---|--|